BioSpace News Archive

Canada’s largest biotechnology company, Vancouver’s STEMCELL Technologies, has been making significant contributions to the fight against COVID-19.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and year ended December 31, 2019, and provided an overview of recent operational highlights.

Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private placement of units which resulted in gross proceeds of $5,984,931 before deducting the placement agent’s fees and estimated offering expenses.

Grant awarded by the Hong Kong Government’s Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu Bi

Life Sciences Investor Forum announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world.

Algernon Pharmaceuticals Inc., is pleased to provide an overview of its multiple recent activities surrounding the investigation of its repurposed drug compound NP-120 (Ifenprodil), as a possible treatment for idiopathic pulmonary fibrosis (IPF), acute lung injury (ALI), chronic cough, and coronavirus (C

Net Revenues Increased 35%; Gross Profit Up 156%, Year-over-Year Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron , Ph.D., as Vice President of Drug Development. Dr. Caron has 30 years of experience in biopharmaceutical development.

Kindred Biosciences, Inc. announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 and interleukin-13, for the treatment of atopic dermatitis in dogs.

Improved Navigation and Functionality Supports Increased Virtual Connectivity with Customers, Collaborators and Growers